Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥20.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥6.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.3bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥6.4bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.3bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥554m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.8bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥790m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥48.5bnat 2023-09-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥36.5bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥21.9bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥26.6bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥24.2bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥18.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥4.4bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.7bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥5.0bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥46.612023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.682023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥46.132023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.332023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio50.0%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥24m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-09-30¥888m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-09-30¥5.9bn
—segment totalrevenue2023-01-01 → 2023-09-30¥20.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥20.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥24m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 682
ItemContextValueUnit
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember37620000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember37620000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-37620000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember11046069000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember1752582000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember12798651000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-37620000JPY
Revenue IFRSPrior1YTDDuration12761031000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember795584000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember698613000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember1494197000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSPrior1YTDDuration1494197000JPY
Finance income IFRSPrior1YTDDuration347752000JPY
Finance costs IFRSPrior1YTDDuration618870000JPY
Profit loss before tax IFRSPrior1YTDDuration1223079000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember18272865000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember2275030000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember20547895000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration20547895000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember23754000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember23754000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-23754000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember18272865000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember2298784000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember20571650000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-23754000JPY
Revenue IFRSCurrentYTDDuration20547895000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000PharmaceuticalReportableSegmentMember5915025000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E05712-000MedicalDeviceReportableSegmentMember887511000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember6802536000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Operating profit loss IFRSCurrentYTDDuration6802536000JPY
Finance income IFRSCurrentYTDDuration505384000JPY
Finance costs IFRSCurrentYTDDuration904311000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-27537000JPY
Profit loss before tax IFRSCurrentYTDDuration6376072000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第23期第３四半期（自　2023年７月１日　至　2023年９月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社ジーエヌアイグループ
Company name in english cover pageFilingDateInstantGNI Group Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)取締役代表執行役社長兼CEO　　イン・ルオ
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目２番２号

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass